JUVENESCENCE Appoints Dr Richard Marshall CBE as CEO
Juvenescence has named Dr Richard Marshall CBE as its new CEO, effective 16 January 2023. Dr Marshall succeeds co-founder Dr Gregory Bailey, who will remain on the company’s board as Executive Chairman.
Dr Marshall brings over twenty years of business leadership to the company, with fifteen years at GSK culminating in his position as Vice President, Head of the Fibrosis & Lung Injury Discovery Performance Unit (DPU). Most recently, Dr Marshall was Senior Vice President, Global Development Head, Respiratory & Immunology of AstraZeneca. Dr Marshall was awarded a CBE in the 2021 Queen’s Honours List for his contribution to UK science and COVID-19.
“I am delighted that Dr Richard Marshall CBE, the former Senior Vice-President, Global Head of Development, Respiratory & Immunology at AstraZeneca, has agreed to lead Juvenescence as CEO. Throughout his career, Richard has been the architect of numerous transformative R&D strategies to drive innovation and deliver rapid growth, with a track record of collegial success, building high performing teams and developing novel therapies,” outgoing CEO Dr Gregory Bailey said. “Richard is a results-oriented leader who believes that in a post-COVID-19 world facing the impending crisis of an inverted demographic pyramid coupled with undercapitalized pension funds and ever-increasing healthcare costs, proactive, decentralized solutions are desperately needed. Juvenescence is a critical player in the mega-trends now driving towards the healthier lifestyles and digital health strategies needed to confront these issues. I am confident that with this appointment, we have a world class team with the experience and skillset to position Juvenescence as one of the premier biotech and pharmaceutical companies focused on modifying aging through prevention.”
Dr Richard Marshall CBE said, “I am thrilled to be joining Juvenescence at such a pivotal point in the company’s history. They are at a real inflection point, with an incredible opportunity to build on Juvenescence’s trusted brand and the Founders’ 30-year history of developing drugs to bring innovative approaches to modify and prevent the impact of aging to the market. With its broad portfolio and depth of experience, Juvenescence is building a unique ecosystem of key partnerships and acquiring the critical capabilities needed for success in this rapidly evolving field. I look forward to working with the team, our partners, and shareholders to capitalize on this incredible opportunity.”
About Juvenescence
Juvenescence is a life sciences company developing therapies to modify aging and increase healthy human lifespan. It was founded by Jim Mellon, Dr Greg Bailey and Dr Declan Doogan. The Juvenescence team consists of highly experienced drug developers, entrepreneurs, marketers, and investors with a significant history of success in pharmaceutical drug development, synthetic biology, and tissue and cellular engineering.
Juvenescence has a broad portfolio of products in development and is driving innovation, with a focus on discovering and developing these therapies to modify the aging process, through prevention and by regenerating damage, to support healthy aging and increase health span. The company is committed to inspiring and equipping the world to, not just reimagine what it means to age, but to help people Reimagine A Lifetime. For more information see: www.JuvLabs.com
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20230116005022/en/
Contact information
About Business Wire
For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
BeOne Medicines Announces Third Quarter 2025 Financial Results and Business Updates6.11.2025 13:00:00 EET | Press release
BeOne Medicines Ltd. (NASDAQ: ONC; HKEX: 06160; SSE: 688235), a global oncology company, today announced financial results and corporate updates from the third quarter of 2025. “These strong financial results reinforce our position as a global oncology leader with exceptional topline growth and a strong balance sheet,” said John V. Oyler, Co-Founder, Chairman and CEO at BeOne. “BRUKINSA is now the global revenue leader in the BTKi class, supported by long-term efficacy and safety data and a growing body of evidence reinforcing its scientific hypothesis of sustained BTK inhibition. Our late-stage hematology portfolio continues to advance with sonrotoclax, a potentially best-in-class BCL2 inhibitor that has demonstrated impressive clinical results, and our BTK CDAC BGB-16673, further strengthening our leadership in B cell malignancies, including CLL. With one of the most promising oncology pipelines in the industry, we are poised to deliver multiple data and regulatory milestones that wi
Shippeo Launches Shippeo AI, Turning Trusted Visibility Into Instant, Intelligent Action6.11.2025 13:00:00 EET | Press release
Shippeo, the leading provider of real-time transportation visibility (RTTV), revealed Shippeo AI today, at its Visibility Now! conference. This brand new intelligent layer of the Shippeo Platform delivers trusted visibility and instant action to empower the people behind global supply chains. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20251106263715/en/ Alongside Shippeo AI, the company revealed a series of product enhancements: an all-new eCMR (Electronic Consignment Note) system; transformed Air Visibility; a deeper user experience for Finished Vehicle Logistics (FVL); and enhanced data accessibility and UX for the Shippeo platform. This raft of innovations reinforces Shippeo’s position as the world’s most trusted multimodal visibility platform. Shippeo AI, for people who keep the world moving… faster Shippeo AI, the new intelligent layer embedded across the entire Shippeo platform, transforms trusted visibility into con
Wireless Mobility Automotive becomes a 100% German-owned company strengthening its role as a trusted Western supplier6.11.2025 12:49:00 EET | Press release
Wireless Mobility, a leading provider of advanced cellular, automotive, smart and short-range modules, today announces that Wireless Mobility Automotive has become a wholly owned subsidiary of Wireless Mobility Holding GmbH, making the company a 100% German-owned enterprise. This milestone reinforces the company’s position as a transparent and independent Western supplier, fully aligned with the US connected vehicle ecosystem and addressing the expectations of global OEMs and tier one suppliers seeking reliable long-term partners. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20251021160513/en/ Norbert Muhrer, CEO, Wireless Mobility “This step underlines our clear commitment to transparency, independence and European quality,” said Norbert Muhrer, CEO of Wireless Mobility. “With German ownership, European engineering, and a global perspective, Wireless Mobility is ready to be the trusted Western supplier the industry has been
Expereo Appoints Noel Hamill as Chief Marketing Officer6.11.2025 11:00:00 EET | Press release
Expereo, the world-leading managed Network as a Service (NaaS) provider that connects people, places and things anywhere, today announces the appointment of Noel Hamill as its Chief Marketing Officer (CMO), a strategic hire to accelerate the company’s growth strategy. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20251106364284/en/ Noel Hamill Hamill joins Expereo with over two decades of marketing leadership experience across global SaaS businesses and consumer brands, including EE and Ladbrokes, PG Forsta and most recently parcelLab, where he served as CMO. In his new role, Hamill will report directly to Ben Elms, CEO, and lead Expereo’s global marketing strategy with a sharp focus on driving growth, expanding market share, and scaling customer acquisition across enterprise and wholesale segments. His appointment underscores Expereo’s commitment to strengthening its brand presence and accelerating adoption of its expereoOne
IFF Benicarló Pioneers On-Site Green Hydrogen Production Facility for Sustainable Fragrance Ingredient Manufacturing6.11.2025 10:00:00 EET | Press release
IFF (NYSE: IFF), a global leader in flavors, fragrances, food ingredients and biosciences, announced the installation of a nature-based hydrogen production facility at its Scent R&D and fragrance ingredients manufacturing plant in Benicarló, Spain. The site has partnered with Iberdrola, one of the world’s largest producers of renewable energy, to become the first in the fragrance industry to rely on renewable electricity for hydrogenation reactions used in manufacturing key fragrance ingredients. Aligned with the company’s commitment to Do More Good for people and planet, the site’s system can make 100 tons of clean hydrogen annually using renewable energy. It includes a built-in compressor to store hydrogen on-site — reducing the Life Cycle Assessment (LCA) of its products and supporting customers worldwide in achieving their decarbonization goals. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20251106888864/en/ Photo credit
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom